Management
Mark A. Sirgo, Pharm. D. : President and Chief Executive Officer
Andrew L. Finn, Pharm.D. : Executive Vice President of Product Development
James A. McNulty, CPA : Chief Financial Officer
Charles E. Dadswell, Esq. : General Counsel
Albert J. Medwar, M.B.A. : Vice President, Marketing
Niraj Vasisht, Ph.D. : Senior Vice President, Product Development & Chief Technology Officer
Mark A. Sirgo, Pharm. D.
President and Chief Executive Officer
Mark A. Sirgo, Pharm.D. has been our President and Chief Executive Officer since July 2005. Dr. Sirgo joined our company in August 2004 as Senior Vice President of Commercialization and Corporate Development upon the acquisition of Arius Pharmaceuticals, of which Dr. Sirgo was a co-founder and Chief Executive Officer. Dr. Sirgo has also served as our Executive Vice President, Corporate and Commercial Development, and Chief Operating Officer. Dr. Sirgo has more than 20 years of experience in the pharmaceutical industry, including 16 years in clinical drug development; seven years in marketing, sales, and business development, and five years in executive management. Prior to his involvement with Arius Pharmaceuticals from 2003 to 2004, he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome, among other accomplishments. From 1996 to 1999, Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc. Dr. Sirgo serves on the Board of Salix Pharmaceuticals (Nasdaq: SLXP), a specialty pharmaceutical company specializing in gastrointestinal products. Dr. Sirgo received his Bachelor of Science in Pharmacy from Ohio State University and his Doctorate from the Philadelphia College of Pharmacy and Science.
Andrew L. Finn, Pharm.D.
Executive Vice President of Product Development
Andrew Finn, Pharm.D. has been our Executive Vice President of Product Development since January 2007. He joined the company in August 2004, upon our acquisition of Arius Pharmaceuticals, of which he was co-founder and Executive Vice President Clinical Development and Regulatory Affairs. Dr. Finn has more than 25 years of experience in pharmaceutical development, and is responsible for the development of BioDelivery Sciences’ portfolio of products (e.g. BEMA® Fentanyl, BEMA® Buprenorphine and Cochleate Amphotericin B) including pharmaceutical development and manufacturing, nonclinical and clinical development, and regulatory affairs. Prior to his involvement with Arius, Dr. Finn was the Executive Vice President of Product Development at POZEN, Inc., where he was responsible for formulation development, non-clinical development, clinical research, regulatory affairs, and for submitting marketing applications in Europe and the United States for two migraine products. He was also the co-founder and Chief Executive Officer of enVision Sciences, a regulatory and clinical service company. Additional previous experience includes his role as the Vice President of U.S. Clinical Research for Solvay Pharmaceuticals, and a number of positions with increasing responsibility during his tenure at Glaxo, Inc. Dr. Finn received his Bachelor of Science in Pharmacy from the University of North Carolina and his Doctorate from the University of Michigan.
James A. McNulty, CPA
Chief Financial Officer
James A. McNulty, CPA, has served as our Secretary, Treasurer and Chief Financial Officer since 2001. He also serves as Chief Financial Officer of Hopkins Capital Group, an affiliation of limited liability companies which engage in venture activities and is Treasurer and Corporate Secretary of Accentia Biopharmaceuticals, Inc. (Nasdaq: ABPI). Mr. McNulty practiced public accounting from 1971 through 1997 and co-founded Pender McNulty & Newkirk, which became one of Florida's largest regional CPA firms and was a founder/principal in two other CPA firms. He served as Chief Financial Officer of Star Scientific, Inc. (Nasdaq: STSI) from October 1998 to May 2000. From June 2000 through January 2002, he served as Chief Financial Officer and Chief Operating Officer of American Prescription Providers, Inc. Mr. McNulty is a graduate of University of South Florida, a licensed Certified Public Accountant and a member of the American and Florida Institutes of CPAs.
Charles E. Dadswell, Esq.
General Counsel
Charles E. Dadswell, Esq. has been our General Counsel since joining the company in January 2008. He is responsible for overseeing all activities pertaining to BioDelivery Sciences’ intellectual property portfolio and contract activities. Mr. Dadswell has over 20 years of pharmaceutical industry experience, including 16 years in intellectual property, four years in sales and marketing, and six years in executive management. Mr. Dadswell previously held numerous positions at Glaxo, Glaxo Wellcome and most recently, at GlaxoSmithKline as the Vice President of U.S. Intellectual Property, where he was responsible for managing GSK’s Research Triangle Park, North Carolina Patent group. In this position he was responsible for the procurement and maintenance of worldwide intellectual property rights including U.S. enforcement of patent portfolios directed to Zofran, Lamictal, Imitrex, Wellbutrin XL, and Zantac Syrup. Mr. Dadswell’s previous experience includes three years as a hospital sale representative and seven years as a hospital Pharmacist where he developed one of the first hospital unit dose programs incorporating small volume liquids and injectables for pediatric and neonatal utilization. Mr. Dadswell received a Bachelor of Science degree in Pharmacy from Ferris State University, a JD from Thomas M. Cooley Law School, and a Masters of Law degree in Patent Law and Trade Regulation from The National Law Center at George Washington University.
Albert J. Medwar, M.B.A.
Vice President, Marketing
Albert J. Medwar, M.B.A. has been our Vice President of Marketing since joining the company in April 2007, with nearly 20 years of experience in marketing, sales, and marketing research. Prior to joining the company, Mr. Medwar was the Head of Oncology Marketing at EMD Pharmaceuticals, the U.S. subsidiary of Merck KGaA, where he was responsible for developing the global market for a pipeline of oncology products. Mr. Medwar was also the Marketing Director for Triangle Pharmaceuticals, a start-up company focusing on the development and commercialization of compounds for HIV and hepatitis. Mr. Medwar’s pharmaceutical career began in sales at Burroughs Wellcome, which later became Glaxo Wellcome. After six years of sales experience, he took on marketing research responsibilities, and then played an important role in the launch of a short acting opioid analgesic, remifentanil, and held increasing marketing responsibility for a number of products including a portfolio of anesthetic/analgesic agents, Zofran, and Wellbutrin SR. Mr. Medwar received a Bachelor of Science degree from Cornell University and a Masters of Business Administration from Bentley College.
Niraj Vasisht, Ph.D.
Senior Vice President, Product Development & Chief Technology Officer
Niraj Vasisht, Ph.D. has been our Senior Vice President of Product Development and Chief Technology Officer since joining the company in February 2005 with over 14 years of experience in pharmaceutical development. In his position, Dr. Vasisht is responsible for the pharmaceutical development, manufacturing and supply chain management for BioDelivery Sciences’ drug portfolio. He directs and oversees the product design, formulation development, quality control, process engineering, and stability testing of the drug product, and is responsible for the chemistry, manufacturing and controls (CMC) section in IND and NDA filings. Prior to joining the company, Dr. Vasisht held positions of increasing responsibility at Southwest Research Institute and was most recently the Director of Microencapsulation, Pharmaceutical Development and Nanomaterials, where he was responsible for leading the group that provides R&D and product development services to pharmaceutical, consumer health, and nutraceutical companies. Dr. Vasisht is the inventor/co-inventor on multiple patents in drug delivery. Dr. Vasisht received a BTech degree in Chemical Engineering from the Indian Institute of Technology at Kanpur, a Masters of Science from the University of New Hampshire and a Doctorate in Chemical Engineering from Rensselaer Polytechnic Institute.